CENTR Brands Corp. Announces Q2 2022 Results
Vancouver, British Columbia--(Newsfile Corp. - January 28, 2022) - CENTR Brands Corp. (CSE: CNTR) (FSE: 303) (OTCQB: CNTRF) (the "Company")...
Day: January 28, 2022
Psyched Wellness Implements RSU Plan and Grant RSUS
Toronto, Ontario--(Newsfile Corp. - January 28, 2022) - Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) (the "Company" or...
Helix BioPharma Corp. Reports Voting Results and Appointment of New Board Director
RICHMOND HILL, ON / ACCESSWIRE / January 28, 2022 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), an immuno-oncology...
ESO Identifies Key Fire Service Trends to Watch in 2022
Focus will be on staffing challenges, community engagement, provider wellness and evolving service delivery models AUSTIN, Texas--(BUSINESS WIRE)--ESO, the leading...
First Patient Recruited for Multi-Year Collaborative Primary Sclerosing Cholangitis (PSC) Pediatric Study Using Perspectum’s Imaging Technology to Help Predict Disease Progression and Guide Patient Management
SAN FRANCISCO--(BUSINESS WIRE)--#Healthcare--Perspectum announced recruitment of the first patient in a multi-center collaborative study to characterize Primary Sclerosing Cholangitis in...
CardieX Engages Integrous Communications as North American Investor Relations Advisor
IRVINE, CA / ACCESSWIRE / January 28, 2022 / CardieX Limited (ASX:CDX)(OTC PINK:CDEXF) ("CardieX" or the "Company",) a global health-technology...
Nutriband Issued Full US Patent for Its Aversa(TM) Abuse Deterrent Transdermal Platform by United States Patent and Trademark Office
ORLANDO, FL / ACCESSWIRE / January 28, 2022 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) today announced the receipt of an Issue Notification...
Sorrento Announces Its Oral SARS-CoV-2 Main Protease (Mpro) Inhibitor, STI-1558, Strongly Neutralizes Omicron
STI-1558, a novel oral Mpro inhibitor, effectively inhibits Omicron virus entry and replication in cells.STI-1558 is orally bioavailable with improved...
Clearmind Medicine Partners with Dr. Gabor Maté to Discuss Alcohol Use Disorder and Trauma in a Special Virtual Event on February 3
A renowned speaker, and bestselling author, Dr. Gabor Maté is highly sought after for his expertise on a range of...
Maravai LifeSciences Acquires MyChem, a Leader in Proprietary Ultra-Pure Nucleotides
MyChem’s nucleotide synthesis methods are highly complementary to Maravai’s TriLink mRNA technologies Increases capabilities serving the high-growth cell and gene...
HTG Appoints Biopharmaceutical Industry Veteran Christopher Kiritsy to its Board of Directors
Brings Significant Operational Experience in Building Therapeutic Drug Development BusinessesTUCSON, Ariz., Jan. 28, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc....
Advaxis Prices Offering of $5,000,000 of Convertible Redeemable Preferred Stock Through a Private Placement
MONMOUTH JUNCTION, N.J., Jan. 28, 2022 (GLOBE NEWSWIRE) -- Advaxis, Inc. (OTCQX: ADXS), a clinical-stage biotechnology company focused on the...
Amryt Announces Oleogel-S10 EMA Regulatory Update
Amryt Announces Oleogel-S10 EMA Regulatory Update Ad-Hoc Expert Group to provide independent EB specific expertise and advice DUBLIN, Ireland, and...
Lava Therapeutics Announces Participation in the SVB Leerink 11th Annual Global Healthcare Conference 2022
UTRECHT, The Netherlands and PHILADELPHIA, Jan. 28, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage biotechnology company...
Algernon Pharmaceuticals Announces Notice of Allowance for Ifenprodil Patent Application for Idiopathic Pulmonary Fibrosis
VANCOUVER, British Columbia, Jan. 28, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW) (OTCQB:...
Philips and University Hospital Brandenburg an der Havel sign 10-year partnership to advance patient care
University Hospital Brandenburg an der Havel January 28, 2022 Major German University Hospital secures long-term access to the latest health...
Oxford Biomedica broadens leading viral vector offerings by incorporating Homology Medicines’ established AAV capabilities into a newly formed AAV Manufacturing and Innovation Business in the US with Homology Medicines as 20% owner
Oxford Biomedica broadens leading viral vector offerings by incorporating Homology Medicines’ established AAV capabilities into a newly formed AAV Manufacturing...
Oxford Biomedica broadens leading viral vector offerings by incorporating Homology Medicines’ established AAV capabilities into a newly formed AAV Manufacturing and Innovation Business in the U.S. with Homology Medicines as 20% owner
Oxford Biomedica and Homology Medicines to establish Oxford Biomedica Solutions LLC, a new U.S.-based AAV Manufacturing and Innovation Business Homology...
Biogen Reaches Agreement with Samsung Biologics to Sell Equity Stake in Their Biosimilar Joint Venture for up to $2.3 billion
The companies will continue with their exclusive agreements, including for commercialization of their current portfolioCAMBRIDGE, Mass., Jan. 27, 2022 (GLOBE...
ALX Oncology Receives U.S. FDA Orphan Drug Designation for Evorpacept for the Treatment of Patients with Gastric Cancer and Gastroesophageal Junction Cancer
SOUTH SAN FRANCISCO, Calif., Jan. 27, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage...